← back to search

William Novotny

Addgene ·
Area of research
Genetics · Pathology and Forensic Medicine
Research interest
Research interests include Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Colorectal Cancer Treatments and Studies, and Chronic Myeloid Leukemia Treatments.
h-index
44
citations
30,698
works
176
NIH funding
primary concept
Medicine
email

Recent publications

Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study
Blood Advances 2023cited by 18position: middledoi
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma
Blood Advances 2021cited by 98position: middledoi
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
Blood Advances 2021cited by 84position: middledoi
Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma
Blood Advances 2021cited by 47position: middledoi
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up
Blood 2020cited by 107position: middledoi
A Phase III Study of Zanubrutinib Plus Rituximab Versus Bendamustine Plus Rituximab in Transplant-Ineligible, Untreated Mantle Cell Lymphoma
Future Oncology 2020cited by 32position: middledoi
A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment
Leukemia & lymphoma/Leukemia and lymphoma 2020cited by 21position: middledoi
Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: Results from a phase II, single-arm, multicenter, study.
Journal of Clinical Oncology 2020cited by 6position: middledoi
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
Nature Medicine 2019cited by 760position: middledoi
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
Blood 2019cited by 366position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Jane Huang · Los Angeles Medical Center5 papers (2019–2021)Constantine S. Tam · Alfred University4 papers (2019–2021)Judith Trotman · Repatriation General Hospital3 papers (2019–2021)Stephen Opat · Monash Health3 papers (2019–2021)Javier Muñoz · Creighton University3 papers (2019–2021)Gavin Cull · Sir Charles Gairdner Hospital3 papers (2019–2021)Ziwen Tan · Jiangxi University of Finance and Economics3 papers (2020–2021)David Simpson · The University of Melbourne3 papers (2019–2021)Aichun Liu · Shandong University of Technology2 papers (2020–2021)Weili Zhao · Shenzhen Institutes of Advanced Technology2 papers (2020–2021)Paula Marlton · The University of Queensland2 papers (2019–2020)John F. Seymour · Peter MacCallum Cancer Centre2 papers (2019–2020)Michael Wang · University of Guelph2 papers (2020–2021)Bing Xiang · Guangxi Medical University2 papers (2020–2021)Yiling Yu · BeiGene (China)2 papers (2019–2020)Haiyi Guo · Kaiser Permanente2 papers (2020–2021)Eric Holmgren · Baylor University Medical Center2 papers (2020–2020)Siminder Atwal · Resolve Therapeutics (United States)2 papers (2020–2021)Huilai Zhang · Tianjin Medical University Cancer Institute and Hospital2 papers (2020–2021)Alessandra Tedeschi · Centro de Investigación Biomédica en Red de Cáncer2 papers (2019–2020)